HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 292/6/E1656    most recent 00502.2006v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Granado, M. Articles by López-Calderón, A. Search for Related Content PubMed PubMed Citation Articles by Granado, M. Articles by López-Calderón, A.

Experimental arthritis inhibits the insulin-like growth factor-I axis and induces muscle wasting through cyclooxygenase-2 activation

Facultad de Medicina, Departamento Fisiología, Universidad Complutense, Madrid, Spain

Submitted 15 September 2006 ; accepted in final form 5 February 2007

Chronic arthritis induces cachexia associated with an inhibition of the growth hormone (GH)-insulin-like growth factor-I (IGF-I) system and an activation of the E3 ubiquitin-ligating enzymes muscle atrophy F-box (MAFbx) and muscle Ring finger 1 (MuRF1) in the skeletal muscle. The aim of this work was to study the role of cyclooxygenase (COX)-2 in chronic arthritis-induced cachexia. Arthritis was induced in rats by Freund's adjuvant injection, and the effects of two COX inhibitors (indomethacin, a nonspecific inhibitor, and meloxicam, a selective COX-2 inhibitor on pituitary GH and on liver and serum IGF-I levels) were tested. Arthritis decreased body weight gain and GH and liver IGF-I gene expression. In the arthritic rats, both inhibitors, indomethacin and meloxicam, prevented the inhibitory effect of arthritis on body weight gain. Indomethacin and meloxicam administration to arthritic rats increased pituitary GH and liver IGF-I mRNA as well as serum levels of IGF-I. These data suggest that induction of COX-2 during chronic inflammation is involved in the inhibition of the GH-IGF-I axis and in the body weight loss. In the gastrocnemius muscle, arthritis increased the gene expression of tumor necrosis factor (TNF)-, the E3 ubiquitin-ligating enzymes MAFbx and MuRF1, as well as of IGF-I and IGF-binding protein-5 (IGFBP-5). Inhibition of COX-2 by meloxicam administration increased gastrocnemius weight and decreased MAFbx, MuRF1, TNF-, and IGFBP-5 gene expression. In summary, our data indicate that chronic arthritis-induced cachexia and muscle wasting are mediated by the COX-2 pathway resulting in a decreased GH-IGF-I secretion and increased expression of MAFbx and MuRF1 mRNA.

indomethacin; meloxicam; tumor necrosis factor-; muscle Ring finger 1; muscle atrophy F-box

This article has been cited by other articles:

				E. Castillero, A. I. Martin, M. Lopez-Menduina, M. A. Villanua, and A. Lopez-Calderon Eicosapentaenoic acid attenuates arthritis-induced muscle wasting acting on atrogin-1 and on myogenic regulatory factors Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2009; 297(5): R1322 - R1331. [Abstract] [Full Text] [PDF]

				M. L Novak, W. Billich, S. M. Smith, K. B. Sukhija, T. J. McLoughlin, T. A. Hornberger, and T. J. Koh COX-2 inhibitor reduces skeletal muscle hypertrophy in mice Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2009; 296(4): R1132 - R1139. [Abstract] [Full Text] [PDF]